PURPOSE: To analyse the influence of the learning curve on dosimetric data for high-dose-rate brachytherapy prostate cancer boost.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
PATIENTS AND METHODS: From February 2009 to May 2012, after a first course of external beam radiation therapy (46Gy/23 fractions), 124 patients underwent high-dose-rate brachytherapy boost using Plato™ (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden). The impact of the learning curve on the dosimetric quality of the prostate implant was assessed. The dosimetric data have been analysed: clinical target volume (CTV), D90 (dose to 90 % of CTV), D100, V100 (part on the CTV receiving 100 % of the dose), V150, V200 and DHI (dose non-homogeneity index). The doses delivered to 0.1, 1 and 2 cm3 of the rectum and urethra were calculated.
RESULTS: During the study period (39 months), a significant reduction of V150 (P< 0.001), V200 (P< 0.001), D0.1rectum (P<0.001), D1rectum (P< 0.001), D2rectum (P< 0.001), D0.1urethra (P< 0.001), and D1urethra (P< 0.002) was observed associated with a significant degradation of the D90 (P< 0.001) but not significant for the V100 (P=0.29) and the D100 (P=0.3).
CONCLUSION: This study confirms that the dosimetric quality of high-dose-rate brachytherapy prostate implant is significantly improved during the learning curve period.
Benhaïm C, Chand ME, Gal J, Hijazi H, Gautier M, Hannoun-Lévi JM. Are you the author?
Département de radiothérapie, centre Antoine-Lacassagne, université Nice-Sophia, 33, avenue de Valombrose, 06000 Nice, France; Département de radiothérapie, centre Jean-Perrin, université d'Auvergne, 58, rue Montalembert, 63000 Clermont-Ferrand, France; Unité de biostatistique, centre Antoine-Lacassagne, université Nice-Sophia, 33, avenue de Valombrose, 06000 Nice, France.
Reference: Cancer Radiother. 2014 Aug 27. pii: S1278-3218(14)00103-6.
Article in French.